Apr 17, 2026
Summary The epidemiological landscape of IMN highlights a substantial disease burden across the seven major markets. According to DelveInsight’s analysis, IMN accounted for approximately 69,000 prevalent cases in 2025, within a broader pool of nearly 87,000 membranous nephropathy cases. This indicates that IMN ...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper